Renalytix AI and University of Utah announce partnership to improve kidney health news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
E-Mail
Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, and the University of Utah, one of the top research institutions in the United States, today announced a partnership to improve kidney health and reduce the risk of kidney failure for large scale populations in the earliest stages of kidney disease.
The partnership intends to implement RenalytixAI s in vitro diagnostic platform, KidneyIntelX, in combination with a range of advanced clinical management solutions to optimize patient care and drive towards improved outcomes system-wide at University of Utah Health, which serves millions of patients in six states. KidneyIntelX is designed for the identification of adults with early-stage chronic kidney disease and diabetes who are at risk for progressive kidney function decline or kidney failure.
The University of Utah and RenalytixAI Partner to Drive Innovation in Kidney Health Innovative partnership to enable health system-wide approach to help delay or prevent progression in the earliest stages while advancing genetics research for detection, prognosis and treatment of chronic kidney disease
February 24, 2021 08:00 ET | Source: Renalytix AI plc. Renalytix AI plc.
NEW YORK and SALT LAKE CITY, Feb. 24, 2021 (GLOBE NEWSWIRE)
Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, and the
University of Utah, one of the top research institutions in the United States, today announced a partnership to improve kidney health and reduce the risk of kidney failure for large scale populations in the earliest stages of kidney disease.
Feb 22, 2021
Systematic review finds some benefits with agent, but supportive data are weak
The anti-diabetic medication metformin led to modest benefits on weight and insulin resistance in children and adolescents with obesity, although the evidence driving that conclusion was of “varying quality,” according to a systematic review from Canada.
The review of two dozen randomized controlled trials (RCTs; n=1,623 patients) showed that metformin resulted in a modest decrease in BMI, BMI z score, and homeostatic model assessment of insulin resistance (HOMA-IR) relative to placebo:
BMI: range of mean values −2.70 to 1.30 versus −1.12 to 1.90.
BMI z score: range of mean values −0.37 to −0.03 versus −0.22 to 0.15.
College students might be allowed to apply for exemptions from vaccinations \u2014 include the COVID-19 vaccine \u2014 that universities may require in the future to attend courses.